8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Insulitis in human type 1 diabetes: lessons from an enigmatic lesion

      review-article
      European Journal of Endocrinology
      Oxford University Press
      type 1 diabetes, islets of Langerhans, autoimmunity, endotype

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Type 1 diabetes is caused by a deficiency of insulin secretion which has been considered traditionally as the outcome of a precipitous decline in the viability of β-cells in the islets of Langerhans, brought about by autoimmune-mediated attack. Consistent with this, various classes of lymphocyte, as well as cells of the innate immune system have been found in association with islets during disease progression. However, analysis of human pancreas from subjects with type 1 diabetes has revealed that insulitis is often less intense than in equivalent animal models of the disease and can affect many fewer islets than expected, at disease onset. This is especially true in subjects developing type 1 diabetes in, or beyond, their teenage years. Such studies imply that both the phenotype and the number of immune cells present within insulitic lesions can vary among individuals in an age-dependent manner. Additionally, the influent lymphocytes are often mainly arrayed peripherally around islets rather than gaining direct access to the endocrine cell core. Thus, insulitis remains an enigmatic phenomenon in human pancreas and this review seeks to explore the current understanding of its likely role in the progression of type 1 diabetes.

          Related collections

          Most cited references76

          • Record: found
          • Abstract: not found
          • Article: not found

          Pathologic anatomy of the pancreas in juvenile diabetes mellitus.

          W Gepts (1965)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Precision diabetes: learning from monogenic diabetes

            The precision medicine approach of tailoring treatment to the individual characteristics of each patient or subgroup has been a great success in monogenic diabetes subtypes, MODY and neonatal diabetes. This review examines what has led to the success of a precision medicine approach in monogenic diabetes (precision diabetes) and outlines possible implications for type 2 diabetes. For monogenic diabetes, the molecular genetics can define discrete aetiological subtypes that have profound implications on diabetes treatment and can predict future development of associated clinical features, allowing early preventative or supportive treatment. In contrast, type 2 diabetes has overlapping polygenic susceptibility and underlying aetiologies, making it difficult to define discrete clinical subtypes with a dramatic implication for treatment. The implementation of precision medicine in neonatal diabetes was simple and rapid as it was based on single clinical criteria (diagnosed <6 months of age). In contrast, in MODY it was more complex and slow because of the lack of single criteria to identify patients, but it was greatly assisted by the development of a diagnostic probability calculator and associated smartphone app. Experience in monogenic diabetes suggests that successful adoption of a precision diabetes approach in type 2 diabetes will require simple, quick, easily accessible stratification that is based on a combination of routine clinical data, rather than relying on newer technologies. Analysing existing clinical data from routine clinical practice and trials may provide early success for precision medicine in type 2 diabetes. Electronic supplementary material The online version of this article (doi:10.1007/s00125-017-4226-2) contains a slideset of the figures for download, which is available to authorised users.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Analysis of islet inflammation in human type 1 diabetes.

              The immunopathology of type 1 diabetes (T1D) has proved difficult to study in man because of the limited availability of appropriate samples, but we now report a detailed study charting the evolution of insulitis in human T1D. Pancreas samples removed post-mortem from 29 patients (mean age 11.7 years) with recent-onset T1D were analysed by immunohistochemistry. The cell types constituting the inflammatory infiltrate within islets (insulitis) were determined in parallel with islet insulin content. CD8(+) cytotoxic T cells were the most abundant population during insulitis. Macrophages (CD68(+)) were also present during both early and later insulitis, although in fewer numbers. CD20(+) cells were present in only small numbers in early insulitis but were recruited to islets as beta cell death progressed. CD138(+) plasma cells were infrequent at all stages of insulitis. CD4(+) cells were present in the islet infiltrate in all patients but were less abundant than CD8(+) or CD68(+) cells. Forkhead box protein P3(+) regulatory T cells were detected in the islets of only a single patient. Natural killer cells were detected rarely, even in heavily inflamed islets. The results suggest a defined sequence of immune cell recruitment in human T1D. They imply that both CD8(+) cytotoxic cells and macrophages may contribute to beta cell death during early insulitis. CD20(+) cells are recruited in greatest numbers during late insulitis, suggesting an increasing role for these cells as insulitis develops. Natural killer cells and forkhead box protein P3(+) T cells do not appear to be required for beta cell death.
                Bookmark

                Author and article information

                Contributors
                Role: Conceptualization
                Journal
                Eur J Endocrinol
                Eur J Endocrinol
                ejendo
                European Journal of Endocrinology
                Oxford University Press (US )
                0804-4643
                1479-683X
                January 2024
                17 January 2024
                17 January 2024
                : 190
                : 1
                : R1-R9
                Affiliations
                Department of Clinical and Biomedical Science, Islet Biology Exeter (IBEx), Exeter Centre of Excellence in Diabetes (EXCEED), University of Exeter Medical School , Exeter EX2 5DW, United Kingdom
                Author notes
                Corresponding author. Email: N.G.Morgan@ 123456exeter.ac.uk

                Conflict of interest: None declared.

                Author information
                https://orcid.org/0000-0003-1537-8113
                Article
                lvae002
                10.1093/ejendo/lvae002
                10824273
                38231086
                14cb6134-c368-446b-ad50-301d32eb94c1
                © The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 01 September 2023
                : 14 November 2023
                : 18 December 2023
                : 18 December 2023
                : 29 January 2024
                Page count
                Pages: 9
                Funding
                Funded by: MRC, DOI 10.13039/501100000265;
                Award ID: 115797
                Award ID: 945268
                Funded by: European Union’s Horizon;
                Funded by: European Federation of Pharmaceutical Industries and Associations, DOI 10.13039/100013322;
                Funded by: Leona M. and Harry B. Helmsley Charitable Trust, DOI 10.13039/100007028;
                Funded by: National Institute for Health, DOI 10.13039/100000002;
                Categories
                Invited Review
                AcademicSubjects/MED00010
                AcademicSubjects/MED00160
                AcademicSubjects/MED00250

                Endocrinology & Diabetes
                type 1 diabetes,islets of langerhans,autoimmunity,endotype
                Endocrinology & Diabetes
                type 1 diabetes, islets of langerhans, autoimmunity, endotype

                Comments

                Comment on this article